Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors

SIMPLE SUMMARY: Approximately 50–60% of patients with chronic myeloid leukemia (CML) achieve a stable deep molecular response (DMR) after tyrosine kinase inhibitor (TKI) therapy. The achievement of DMR is a prerequisite for treatment-free remission. Repurposing statins is a straightforward strategy...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Hyeok-Jae, Woo, Young-Min, Naka, Kazuhito, Park, Jong-Ho, Han, Ho-Jae, Kim, Hee-Jin, Kim, Sun-Hee, Ahn, Jae-Sook, Kim, Taehyung, Kimura, Shinya, Zarabi, Sarah, Lipton, Jeffrey H., Minden, Mark D., Jung, Chul-Won, Kim, Hyeoung-Joon, Kim, Jong-Won, Kim, Dennis Dong Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582667/
https://www.ncbi.nlm.nih.gov/pubmed/34771705
http://dx.doi.org/10.3390/cancers13215543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582667/
https://www.ncbi.nlm.nih.gov/pubmed/34771705
http://dx.doi.org/10.3390/cancers13215543

Ejemplares similares